NYSE - Delayed Quote USD

Abbott Laboratories (ABT)

Compare
112.23 -1.41 (-1.24%)
At close: 4:00 PM EDT
112.00 -0.23 (-0.20%)
After hours: 5:40 PM EDT
Loading Chart for ABT
DELL
  • Previous Close 113.64
  • Open 113.50
  • Bid 112.23 x 800
  • Ask 112.26 x 800
  • Day's Range 111.79 - 113.51
  • 52 Week Range 89.67 - 121.64
  • Volume 3,422,280
  • Avg. Volume 6,025,901
  • Market Cap (intraday) 195.269B
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) 35.40
  • EPS (TTM) 3.17
  • Earnings Date Oct 16, 2024
  • Forward Dividend & Yield 2.20 (1.94%)
  • Ex-Dividend Date Oct 15, 2024
  • 1y Target Est 124.53

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

www.abbott.com

114,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ABT

View More

Performance Overview: ABT

Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ABT
3.51%
S&P 500
19.50%

1-Year Return

ABT
19.67%
S&P 500
32.92%

3-Year Return

ABT
1.20%
S&P 500
30.82%

5-Year Return

ABT
53.86%
S&P 500
97.39%

Compare To: ABT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ABT

View More

Valuation Measures

Annual
As of 10/2/2024
  • Market Cap

    197.72B

  • Enterprise Value

    205.26B

  • Trailing P/E

    35.85

  • Forward P/E

    21.98

  • PEG Ratio (5yr expected)

    4.15

  • Price/Sales (ttm)

    4.88

  • Price/Book (mrq)

    5.03

  • Enterprise Value/Revenue

    5.04

  • Enterprise Value/EBITDA

    19.81

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.65%

  • Return on Assets (ttm)

    6.26%

  • Return on Equity (ttm)

    14.44%

  • Revenue (ttm)

    40.73B

  • Net Income Avi to Common (ttm)

    5.54B

  • Diluted EPS (ttm)

    3.17

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.22B

  • Total Debt/Equity (mrq)

    37.53%

  • Levered Free Cash Flow (ttm)

    5.39B

Research Analysis: ABT

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 10.38B
Earnings 1.3B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

105.23 Low
124.53 Average
112.23 Current
143.00 High
 

Company Insights: ABT

Research Reports: ABT

View More
  • Abbott and Reckitt: Latest Infant Formula Judgment Against Abbott Weighs on Shares

    Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

    Rating
    Price Target
     
  • Abbott and Reckitt: Latest Infant Formula Judgment Against Abbott Weighs on Shares

    Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

    Rating
    Price Target
     
  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, Grab Holdings worth grabbing now; examining medical-device makers' moat; a hard look at software makers' moat; and Vesync, Macy's, and Travelers Companies.

     
  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, Grab Holdings worth grabbing now; examining medical-device makers' moat; a hard look at software makers' moat; and Vesync, Macy's, and Travelers Companies.

     

People Also Watch